
Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.